An integrative analysis reveals the prognostic value and potential functions of PSMD11 in hepatocellular carcinoma
Molecular Carcinogenesis · 2023-09 · 62 (9) · 1355-1368
DOI: 10.1002/mc.23568 ↗At a glance
Journal article in Molecular Carcinogenesis, published online on 2023-05-22. Written by Cong Zhang and 7 co-authors. Institution: Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejia…. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms. Cited 8 times so far (Crossref); 48 references.
Abstract (original language)
The global burden of hepatocellular carcinoma (HCC) as a preeminent etiology of cancer‐related mortalities sheds light on the imperative necessity for a more profound comprehension of its fundamental biological mechanisms. In this context, the precise function of the 26S proteasome non‐ATPase regulatory subunit 11 (PSMD11) in HCC remains equivocal. To address this vital knowledge gap, we interrogated the cancer genome atlas, genotype‐tissue expression, International cancer genome consortium, gene expression omnibus, the cancer cell line encyclopedia, and tumor immune single‐cell hub databases to evaluate the expression pattern of PSMD11, further confirmed by reverse‐transcription quantitative polymerase chain reaction (RT‐qPCR) in LO2, MHCC‐97H, HepG2, and SMMC7721 cell lines. Additionally, we meticulously assessed the clinical significance and prognostic value of PSMD11, while also exploring its potential molecular mechanisms in HCC. Our findings demonstrated that PSMD11 was highly expressed in HCC tissues, correlating with pathologic stage and histologic grade, thereby conferring a poor prognosis. Mechanistically, PSMD11 appears to exert its tumorigenic effects through the modulation of tumor metabolism‐related pathways. Impressively, low PSMD11 expression was associated with increased immune effector cell infiltration, heightened responsiveness to molecular targeted drugs such as dasatinib, erlotinib, gefitinib, and imatinib, as well as reduced somatic mutation rate. Additionally, we demonstrated that PSMD11 might modulate HCC development through intricate interactions with cuproptosis‐related genes ATP7A, DLAT, and PDHA1. Our comprehensive analyses collectively suggest that PSMD11 represents a promising therapeutic target in HCC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
- Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, Zhejiang Province, China.
- Zhejiang Provincial Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, Zhejiang Province, China.
- Department of Ophthalmology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
- Zhejiang University Cancer Center, Hangzhou, Zhejiang, China.
Cite
APA
Zhang, C., Xu, T., Ji, K., Cao, S., Cao, Y., Ai, J., Jing, L., & Sun, J. H. (2023). An integrative analysis reveals the prognostic value and potential functions of PSMD11 in hepatocellular carcinoma. Molecular Carcinogenesis, 62(9), 1355-1368. https://doi.org/10.1002/mc.23568
Vancouver
Zhang C, Xu T, Ji K, Cao S, Cao Y, Ai J, et al. An integrative analysis reveals the prognostic value and potential functions of PSMD11 in hepatocellular carcinoma. Molecular Carcinogenesis. 2023;62(9):1355-1368. doi:10.1002/mc.23568
BibTeX
@article{Zhang2023,
author = {Zhang, Cong and Xu, Tiantian and Ji, Kun and Cao, Shoujin and Cao, Yunbo and Ai, Jing and Jing, Li and Sun, Jun-Hui},
title = {An integrative analysis reveals the prognostic value and potential functions of PSMD11 in hepatocellular carcinoma},
journal = {Molecular Carcinogenesis},
year = {2023},
volume = {62},
number = {9},
pages = {1355--1368},
doi = {10.1002/mc.23568}
}
EUVIMED